Description: A mini report identifying drivers and barriers to sustaining financial performance over the next 5 years for the top five global pharmaceutical companies -Johnson & Johnson, Pfizer, GSK, Novartis and Sanofi-Aventis This report presents the cases of the top five global pharma companies: J&J, Pfizer, GSK, Novartis and SanofiAventis and identifies their key growth areas. Pooling data from 6 major investment institutions, it delivers a 360o analysis on these big five global pharma with
Words: 1107 - Pages: 5
intermediate steps in the hierarchy. For my research, I have chosen Pfizer and will explain its segmentation process using Lipitor as an example. Pfizer: Pfizer is one of the world’s largest pharmaceutical company with its portfolio including human and biologic, small molecular medicines, vaccines, nutritional and consumer products. It is located in more than 150 countries with it’s headquarter in New York. Pfizer acquired Wyeth in October ’09 for $68 billion. Its main
Words: 1436 - Pages: 6
Abstract The subject of this paper is the quality management of two pharmaceutical companies, Pfizer and Johnson & Johnson. The two companies are said to provide the best possible care to the consumer in areas of health in the global market as well as the domestic market. Effects of Quality Management on Domestic and Global Competition The subject of this paper is on the pharmaceutical company of Pfizer pharmaceuticals and the Johnson & Johnson Company. Both companies are well known in the drug
Words: 726 - Pages: 3
the 70’s. Xanax was first approved by the FDA as an antidepressant, but the FDA came back and told Upjohn that they could distribute it as an antianxiety drug. Pharmacia acquired Upjohn and continued to manufacture Xanax. Xanax is now produced by Pfizer, the company that acquired Pharmacia (PMMEDIA, 2009). Usage Xanax is used to treat people with anxiety disorder. This medication is not recommended for people just dealing with stress or anxiety from everyday stressors. Panic disorders are the
Words: 393 - Pages: 2
mouthwash that was launched by Warner Lambert in 1977 and it was a direct competitor to Scope, it had nearly the same characteristics as Scope with a 12% of the market share during that time. But the major competitor for Scope was Plax, a brand by Pfizer Inc, which was launched in Canada in 1988 on a platform quite different from the traditional mouthwashes, and gained a 10% share since launched. Plax detergents were supposed to help loosen plaque to make brushing effective. Before the entry of Plax
Words: 812 - Pages: 4
Submission and Declaration Learner name: Maddie Johnson | Assessor name: Lesha Stryleki | Issue date: 17/09/15 | Submission date: 09/10/15 | Submitted on: 5/10/15 | Programme: | Unit: | Assignment reference and title:The organisation Pfizer assignment | Please list the evidence submitted for each task. Indicate the page numbers where the evidence can be found or describe the nature of the evidence Task ref. | Evidence submitted | Page numbers ordescription | | | |
Words: 1523 - Pages: 7
Case 25: Pfizer Porsha Erwin Angel Harvey Curtis Hubbard DeMontrez Johnson Michael Kitchens China Thomas 1 Table of Contents History……………………………………………………………………………..Page 3 Summary…………………………………………………………………………..Page 3 General Environment Analysis……………………………..……………………Page 5 Industry Environment Analysis………………………………………………….Page 6 EFE Matrix………………………………………………………………………..Page 9 Internal Competencies …………………………………………………………...Page 10 IFE Matrix………………………………………………………………………...Page 12
Words: 2443 - Pages: 10
Pfizer Stock Analysis Pfizer (NYSE: PFE) is involved in the development, manufacturing and marketing of pharmaceutical products. The industry is intensely competitive and there are a few unique characteristics. Pharmaceutical products have long and expensive development periods – upwards of ten years and $100 million depending on the nature of the drug and the scope of the clinical trials process. In order to encourage companies to engage in innovation, companies are given lengthy patent
Words: 1245 - Pages: 5
Current policy and strategy of Pfizer Company The Pfizer Company planning to implement the following strategies due to its lost: Strategic priorities of the merger: Strengthens platforms for improved, consistent and stable earnings growth (1) Definitively address revenue loss from the loss of exclusivity from hypertension drug Lipitor; (2) Forms broad, diversified portfolio of growth drivers; and (3) Supports continuing progress in establishing a lower, more flexible cost base
Words: 333 - Pages: 2
Pfizer Pharmaceuticals Submitted By: Latrell Jackson December 16, 2013 Submitted To: Dr. Diane Hamilton BA 530 Pfizer Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. Pfizer's products include Lipitor (atorvastatin, used to lower LDL blood cholesterol); Lyrica (pregabalin, for neuropathic pain/fibromyalgia); Diflucan (fluconazole
Words: 826 - Pages: 4
